BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $152.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2014-03-31 was $43.00M, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2013-12-31 was $177.00M.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2013-09-30 was $43.00M.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2013-06-30 was $43.00M.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $152.00M, a 47.77% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $291.00M, a 19.75% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $243.00M, a 71.13% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $142.00M, a 13.94% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $152.00M 10-K · filed 2026-02-11 | ||||
| 2024-12-31 | $291.00M 10-K · filed 2026-02-11 | ||||
| 2023-12-31 | $243.00M 10-K · filed 2026-02-11 | ||||
| 2022-12-31 | $142.00M 10-K · filed 2025-02-12 | ||||
| 2021-12-31 | $165.00M 10-K · filed 2024-02-13 | ||||
| 2020-12-31 | $165.00M 10-K · filed 2023-02-14 | ||||
| 2019-12-31 | $138.00M 10-K · filed 2022-02-09 | ||||
| 2018-12-31 | $138.00M 10-K · filed 2021-02-10 | ||||
| 2017-12-31 | $144.00M 10-K · filed 2020-02-24 | ||||
| 2016-12-31 | $144.00M 10-K · filed 2019-02-25 | ||||
| 2015-12-31 | $132.00M 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $131.00M 10-K · filed 2017-02-21 | ||||
| 2014-03-31 | $43.00M 10-Q · filed 2014-04-29 | $220.00M derived: sum of 2 quarters · filed 2016-02-12 | $263.00M derived: sum of 3 quarters · filed 2016-02-12 | $306.00M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2013-12-31 | $177.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $220.00M derived: sum of 2 quarters · filed 2016-02-12 | $263.00M derived: sum of 3 quarters · filed 2016-02-12 | $220.00M 10-K · filed 2016-02-12 | $181.00M 10-K · filed 2014-02-14 |
| 2013-09-30 | $43.00M 10-Q · filed 2013-10-23 | $86.00M derived: sum of 2 quarters · filed 2013-10-23 | $43.00M 10-Q · filed 2014-10-24 | ||
| 2013-06-30 | $43.00M 10-Q · filed 2013-07-25 | $43.00M 10-Q · filed 2014-07-24 | |||
| 2013-03-31 | $43.00M 10-Q · filed 2013-04-25 | ||||
| 2012-12-31 | $31.00M 10-K · filed 2015-02-13 | ||||
| 2011-12-31 | $69.00M 10-K · filed 2014-02-14 | ||||
| 2010-12-31 | $61.00M 10-K · filed 2013-02-15 | ||||
| 2009-12-31 | $81.00M 10-K · filed 2012-02-17 | ||||
| 2008-12-31 | $84.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |